Richard Piekarz

Richard Piekarz

UNVERIFIED PROFILE

Are you Richard Piekarz?   Register this Author

Register author
Richard Piekarz

Richard Piekarz

Publications by authors named "Richard Piekarz"

Are you Richard Piekarz?   Register this Author

58Publications

1474Reads

30Profile Views

Entinostat: a promising treatment option for patients with advanced breast cancer.

Future Oncol 2017 Jun 9;13(13):1137-1148. Epub 2017 Mar 9.

Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2016-0526DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618943PMC
June 2017

CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio.

Clin Cancer Res 2015 May;21(10):2195-7

Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2555DOI Listing
May 2015

Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma.

Clin J Oncol Nurs 2012 Apr;16(2):195-204

Medical Oncology Branch at Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1188/12.CJON.195-204DOI Listing
April 2012

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

Blood 2011 Jun 25;117(22):5827-34. Epub 2011 Feb 25.

Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health/DHHS, 6130 Executive Blvd., Rockville, MD 20852, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2010-10-31
Publisher Site
http://dx.doi.org/10.1182/blood-2010-10-312603DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112033PMC
June 2011

Clinical Toxicities of Histone Deacetylase Inhibitors.

Pharmaceuticals (Basel) 2010 Aug 26;3(9):2751-2767. Epub 2010 Aug 26.

Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ph3092751DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034096PMC
August 2010

Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Cell Cycle 2010 May 15;9(9):1830-8. Epub 2010 May 15.

Cell & Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.9.9.11543DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659113PMC
May 2010

Religious tradition and concern for the welfare of all living beings.

JAMA 2010 May;303(20):2033-4; author reply 2034

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2010.664DOI Listing
May 2010

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report.

Haematologica 2009 Nov 16;94(11):1618-22. Epub 2009 Jul 16.

Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria 3002, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2009.008607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770976PMC
November 2009

Epigenetic modifiers: basic understanding and clinical development.

Clin Cancer Res 2009 Jun 9;15(12):3918-26. Epub 2009 Jun 9.

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-2788DOI Listing
June 2009

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.

Clin Cancer Res 2009 Feb;15(4):1496-503

Clinical Pharmacology Program, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-1215DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707030PMC
February 2009

Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.

Cancer J 2007 Jan-Feb;13(1):30-9

Molecular Therapeutic Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1903, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e31803c73ccDOI Listing
June 2007

Histone deacetylase inhibitors in combinations: will the preclinical promises be kept?

Cancer J 2007 Mar-Apr;13(2):80-3

Molecular Therapeutics Section, Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e318063bd9fDOI Listing
June 2007

Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.

Clin Cancer Res 2006 Jun;12(12):3762-73

Center for Cancer Research and Cancer Therapeutics Evaluation Program, National Cancer Institute and National Heart Lung and Blood Institute, NIH, Bethesda, Maryland 20892-1903, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-2095DOI Listing
June 2006

Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).

Clin Cancer Res 2006 Mar;12(5):1547-55

Cancer Therapeutics Branch, Center for Cancer Research, NIH, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-1423DOI Listing
March 2006

Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry.

J Chromatogr B Analyt Technol Biomed Life Sci 2004 Sep;809(1):81-6

Clinical Pharmacology Research Core, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S157002320400489
Publisher Site
http://dx.doi.org/10.1016/j.jchromb.2004.06.007DOI Listing
September 2004

A review of depsipeptide and other histone deacetylase inhibitors in clinical trials.

Curr Pharm Des 2004 ;10(19):2289-98

Cancer Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612043383980DOI Listing
August 2004

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.

Blood 2004 Jun 2;103(12):4636-43. Epub 2004 Mar 2.

Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute/NIH, MSC 1903, 10 Center Drive, Building 10/Room 12C103, Bethesda, MD 20892-1903, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2003-09-3068DOI Listing
June 2004